Delivery Order SPE2DB22D3010-SPE2DB25FP2SV
- Not listed
- The U.S. Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Lynparza 150 mg tablets (120 count) valued at $31,702.80. This firm fixed-price delivery order is scheduled for completion by August 25, 2025, with performance at the contractor's facility in Conshohocken, Pennsylvania. The award was made through open competition with no set-aside designation. This delivery order is issued under...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $31,702.80 on June 16, 2025, for the supply of Lynparza 150 mg tablets (120-count units). This firm fixed-price, competitively awarded contract has a completion date of July 9, 2025, and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting open competition among qualified pharmaceutical distributors. This...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $10,543.70 for 60 tablets of Lynparza 100 mg on July 30, 2025, with an ultimate completion date of August 20, 2025. This firm fixed price delivery order was competitively awarded with no set-aside designation and is being fulfilled from AmerisourceBergen's Conshohocken, Pennsylvania location. The contract represents a continuation of pharmaceutical supply services under AmerisourceBergen's broader federal...
- The Defense Logistics Agency awarded a $42,270.40 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Lynparza 150 mg tablets (120-count units) on August 12, 2025, with an ultimate completion date of September 3, 2025. This non-competitive delivery order is being fulfilled from AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The place of...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of LYNPARZA 150 mg tablets in quantities of 60s, with a ceiling value of $10,499.34. This firm fixed-price delivery order, with an ultimate completion date of September 8, 2025, represents a competitive, non-set-aside award to the prime contractor. AmerisourceBergen, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will...
- The Defense Logistics Agency awarded a delivery order valued at $10,567.60 to AmerisourceBergen Drug Corp for the supply of Lynparza 150 mg tablets (120-count units). The contract was awarded on August 12, 2025, with an ultimate completion date of September 3, 2025, and is structured as a firm fixed-price delivery order with no set-aside designation. The pharmaceutical product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, the company's corporate headquarters...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $10,519.62 for 120 tablets of Lynparza 100 mg on July 21, 2025, with an ultimate completion date of August 11, 2025. This firm fixed-price delivery order represents a competitively awarded, non-set-aside transaction executed under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The product will be performed...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $5,249.67 to supply Lynparza 150 mg tablets (60-count units) under a firm fixed-price contract. The delivery order, issued on August 1, 2025, with an ultimate completion date of August 22, 2025, represents a non-set-aside, competitively awarded procurement. The place of performance is listed as Conshohocken, Pennsylvania, which serves as AmerisourceBergen Drug Corp's corporate headquarters and primary...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of LYNPARZA 150 mg tablets in quantities of 60 units. This contract, valued at $10,499.34, represents a firm fixed-price delivery order with an ultimate completion date of September 22, 2025. The award was made through open competition with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, fulfills this order through its...
- The Defense Logistics Agency awarded a delivery order valued at $10,567.60 to AmerisourceBergen Drug Corp for the supply of Lynparza 150 mg tablets (120-count units). This is a firm fixed price delivery order with no set-aside designation, competitively awarded to support federal medical procurement. The contract was awarded on September 2, 2025, with an ultimate completion date of September 23, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as the prime...
- SPE2DB22D3010Indefinite Delivery Contract
- SPE2DB22D3010-SPE2DB25FP2SVDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 18, 2025, for the supply of Lynparza 150 mg tablets (120-count units) valued at $10,567.60, with completion expected by July 11, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be fulfilled from the vendor's facility in Conshohocken, Pennsylvania. The contract represents a continuation of AmerisourceBergen's role as a critical pharmaceutical supplier to the federal government, particularly supporting military and veteran healthcare systems through the Defense Logistics Agency's Medical Supply Chain. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, valued at $999,999,999.00 through December 2026. This prime contract vehicle enables the company to supply a comprehensive range of pharmaceutical products and medical supplies globally to support military healthcare programs, including specialty medications, brand-name and generic drugs, and medical devices. The arrangement positions AmerisourceBergen as a key vendor for the Defense Health Agency and other federal healthcare systems, reflecting its established capability to meet competitive federal procurement requirements across diverse therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $10.6k | 6/18/25 |